THW News and Press, Tekla World Healthcare Fund Shares of Beneficial Interest From 07/09/19

Biotechs and biopharma players are modestly in the green after a D.C. district court stopped a Trump administration initiative requiring drug makers to disclose list prices in television advertisements. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & ...

Oral arguments start today in the U.S. Fifth Circuit Court of Appeals in a case led by Republican Attorneys General to invalidate the Affordable Care Act, known as Obamacare. More news on: The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, BlackRock Health Scie...

Biopharma and biotech players are mostly in the red (again) ahead of an expected executive order from President Trump aimed at corralling U.S. drug prices. Specifically, the order will contain a "favored nation" clause that will be the basis for Medicare reimbursement, i.e., the reimbursem...

Early July is typically one of the two times each calendar year that U.S. drugmakers hike prices. Yesterday, on cue, many appeared to do just that . More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., ProShares Ultra Nasdaq Biotechnology ETF, Healthcare stocks news, Stocks on...

Iowa, Kansas, Maryland, West Virginia and Wisconsin have joined 39 other U.S. states suing Purdue Pharma over its role in the opioid crisis via its promotion of OxyContin (oxycodone hydrochloride). More news on: The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund,...

This article was first released to CEF/ETF Income Laboratory subscribers 2 weeks ago, so data may be out of date. Please check latest data before making investment decisions. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price moveme...

The FDA has completed its long-anticipated guidance on interchangeability of biosimilars, allowing their substitution for reference biologics without prescribers' sign-off. More news on: AbbVie Inc., ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tru...

In lockstep with the U.S., Canadian officials are poised to implement a new initiative aimed at corralling high prescription drug costs, despite an offer by drug makers to pay C$8.6B (US$6.6B) over 10 years, freeze prices or reduce the cost of treating rare diseases. More news on: ProSha...

Following through on its commitment to promote lower drug costs, the Trump administration announces that pharmaceutical and biotech companies will be required to disclose prices in television commercials for medications covered by Medicare that cost more than $35 for a month's supply (mean...

The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) announce the CMS Primary Cares Initiative , a new set of payments that they say will lower administrative costs and enable primary care doctors to spend more time caring for pat...